Copy to clipboard 
Episurf Medical is investigating the opportunities for launching an implant system for the MTP joint of the foot in the US market. Episurf Medical has identified this market as one with significant unmet medical needs. The company has begun the product development phase, and targets the filing of an FDA 510(k) application for the Episealer® MTP system in late 2022 or first half of 2023.
“We are constantly reviewing the options for expansion of the targeted indications for our technology, and I am pleased that we now are taking the next step with a potential implant system for the MTP joint. We have demonstrated that we are efficient and successful in our product development efforts and we are now allocating resources to this highly interesting market segment. The US market for big toe implants is worth an estimated USD 400 million, and we believe that current options available to patients and surgeons are less than optimal. We are committed to explore this opportunity fully, as we believe we can create a highly competitive product. Further, without a doubt, COVID-19 has made us intensify our product development work and the pandemic has emphasised the need to reach to the US market as fast as possible with superb orthopaedic solutions,” said Pål Ryfors, CEO Episurf Medical.
“As the positive clinical results for the Episealer® knee implants continue to mount, orthopaedic surgeons concentrating across a range of anatomic locations are beginning to see the benefits of Episurf Medical’s technologies. Solutions that avoid fusion in the big toe continue to attract interest, and we believe that by utilising advanced imaging and individualised implants we may be able to play a role in the treatment of a group of patients that often are unsatisfied with currently available options,” said Patrick Jamnik, President of Episurf Medical, Inc.
Source: Episurf Medical Inc.
Episurf Medical is investigating the opportunities for launching an implant system for the MTP joint of the foot in the US market. Episurf Medical has identified this market as one with significant unmet medical needs. The company has begun the product development phase, and targets the filing of an FDA 510(k) application for the Episealer® MTP...
Episurf Medical is investigating the opportunities for launching an implant system for the MTP joint of the foot in the US market. Episurf Medical has identified this market as one with significant unmet medical needs. The company has begun the product development phase, and targets the filing of an FDA 510(k) application for the Episealer® MTP system in late 2022 or first half of 2023.
“We are constantly reviewing the options for expansion of the targeted indications for our technology, and I am pleased that we now are taking the next step with a potential implant system for the MTP joint. We have demonstrated that we are efficient and successful in our product development efforts and we are now allocating resources to this highly interesting market segment. The US market for big toe implants is worth an estimated USD 400 million, and we believe that current options available to patients and surgeons are less than optimal. We are committed to explore this opportunity fully, as we believe we can create a highly competitive product. Further, without a doubt, COVID-19 has made us intensify our product development work and the pandemic has emphasised the need to reach to the US market as fast as possible with superb orthopaedic solutions,” said Pål Ryfors, CEO Episurf Medical.
“As the positive clinical results for the Episealer® knee implants continue to mount, orthopaedic surgeons concentrating across a range of anatomic locations are beginning to see the benefits of Episurf Medical’s technologies. Solutions that avoid fusion in the big toe continue to attract interest, and we believe that by utilising advanced imaging and individualised implants we may be able to play a role in the treatment of a group of patients that often are unsatisfied with currently available options,” said Patrick Jamnik, President of Episurf Medical, Inc.
Source: Episurf Medical Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
